Schell T D, Lippolis J D, Tevethia S S
Department of Microbiology and Immunology, Pennsylvania State University College of Medicine, Hershey 17033, USA.
Cancer Res. 2001 Feb 1;61(3):873-9.
Recent reports have documented the presence of SV40 large T antigen (T ag) sequences in a number of human tumors and raised the question of whether cellular immunity to T ag is elicited in such individuals. We used HLA-A2.1 transgenic C57BL/6 mice to identify an epitope from T ag recognized by CD8+ CTLs when presented by this human MHC class I molecule. Immunization of HLA-A2.1 transgenic mice with syngeneic T ag-transformed cells resulted in the induction of HLA-A2.1-restricted, T ag-specific CTLs. The target epitope, residues 281-289 (KCDDVLLLL) of T ag, was identified using both cell lines expressing T ag variants and synthetic T ag peptides. Peptide 281-289 bound stably to HLA-A2.1 molecules, effectively sensitized target cells for CTL lysis, and was efficiently processed from endogenous T ag in cells of both mouse and human origin. CTLs were not cross-reactive on the human BK or JC virus T ags. Thus, SV40 T ag 281-289 represents a potential specific CTL recognition epitope for humans.
最近的报告记录了在许多人类肿瘤中存在SV40大T抗原(T抗原)序列,并提出了在这些个体中是否会引发针对T抗原的细胞免疫的问题。我们使用HLA - A2.1转基因C57BL / 6小鼠来鉴定当由这种人类I类MHC分子呈递时被CD8 + CTL识别的来自T抗原的一个表位。用同基因T抗原转化细胞免疫HLA - A2.1转基因小鼠导致诱导出HLA - A2.1限制性的、T抗原特异性的CTL。使用表达T抗原变体的细胞系和合成的T抗原肽确定了靶表位,即T抗原的281 - 289位残基(KCDDVLLLL)。肽281 - 289与HLA - A2.1分子稳定结合,有效地使靶细胞对CTL裂解敏感,并且从小鼠和人源细胞中的内源性T抗原有效加工而来。CTL对人类BK或JC病毒T抗原无交叉反应。因此,SV40 T抗原281 - 289代表了人类潜在的特异性CTL识别表位。